Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial

AIMS: This analysis evaluated HbA(1c)-adjusted hypoglycemia risk with glargine versus neutral protamine Hagedorn (NPH) over a 5-year study in patients with Type 2 diabetes mellitus (T2DM). Clinical significance was assessed using number needed to harm (NNH) to demonstrate the risk of one additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Fonseca, Vivian, Schinzel, Stefan, Dain, Marie-Paule, Mullins, Peter, Riddle, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802045/
https://www.ncbi.nlm.nih.gov/pubmed/24856612
http://dx.doi.org/10.1016/j.jdiacomp.2014.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802045/
https://www.ncbi.nlm.nih.gov/pubmed/24856612
http://dx.doi.org/10.1016/j.jdiacomp.2014.04.003

Ejemplares similares